Our website uses cookies to bring you an easy and personalised browsing experience. By continuing, you consent to our cookie policy on this device. For More info, please see our Privacy Statement

ICECaP 2024

Welcome & Movember’s Partnership

Professor Chris Sweeney & Sarah Weller

Director of the South Australian immunoGENomics Cancer Institute (SAiGENCI), University of Adelaide
&
Global Director, Prostate Cancer (Movember

ICECaP 2024

Welcome & Movember’s Partnership

ICECaP Adjuvant – Review of submitted & published papers as well as plans for docetaxel and short vs. long term ADT by ICECaP High Risk Classification 1 vs 2-3 vs CN1

Defining detrimental impact of PSA Relapse – Progress in credentialing the decreased detrminetal effects associated with decreased PSA relapse as an endpoint in adjuvant prostate cancer trials

STOPCAP: Treatment Effect – IPD meta-analyses to help determine which men with mHSPC should receive second-generation anti-androgens, docetaxel or their combination

STOPCAP: Prognostic Models & Surrogacy – Assessing Intermediate Clinical Endpoints (ICE) as potential surrogates for Overall Survival (OS) in Subgroups of men with Metastatic Hormone Sensitive Prostate Cancer

ICECaP Biology – Updates on translational research from CHAARTED-STAMPEDE-ENZAMET

ICECaP Biology – Plans for ‘Omics-ICECaP’; MSTIR

ICECaP 2023

Updates from ICECaP: Adjuvant Localized Prostate Cancer

Progress in credentialing the decreased detrimental effects associated with decreased PSA relapse as an endpoint in adjuvant prostate cancer trials

STOPCAP M1: IPD meta-analyses to help determine which men with mHSPC should receive second-generation anti-androgens, docetaxel or their combination

Assessing Intermediate Clinical Endpoints (ICE) as Potential Surrogates for Overall Survival (OS) in Subgroups of men with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Discovery and qualification of multi-modality biomarkers for men starting long-term ADT in the STAMPEDE trial

Update on CHAARTED and ENZAMET Translational Science

ICECaP 2022

Multi-national collaborative strategies for validating a biomarker for HSPC

Next Steps for ICECaP2: Planned analyses of different treatment effects in subgroups and exploring earlier intermediate clinical endpoints

Using surrogate outcomes to demonstrate value in adjuvant prostate cancer: An update

HARMONIZATION Progress of writing a guidance document for conduct of adjuvant prostate cancer trials

STOPCaP: Treatment effect - Progress on IPD data collection and network meta-analyses for treatment effects

Identification of Surrogate Endpoints and Developing and Validating Prognostic Models in Metastatic Hormone Sensitive Prostate Cancer

ICECaP 2021

Opening Remarks

ICECaP Updates

Update on data collection for ICECaP2

Example of assessing new PSA based endpoints

Progress on creating a health economics model in adjuvant prostate cancer setting

Discuss goal to credential QALY gained from preventing a PSA relapse as an endpoint

Progress of writing a guidance document for conduct of adjuvant trials

Progress on IPD data collection and network meta-analyses for treatment effects

Progress on prognostic models and surrogacy

Proposal of simple prognostic model

ICECaP Biology 2021